Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: What Early-Phase Trials Suggest

Posted: Wednesday, September 27, 2017

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses three early-phase studies on various agents, including daratumumab, carfilzomib, lenalidomide, and others, and how these findings may influence the options available to newly diagnosed patients.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.